Practice bulletin no. 109: Noncontraceptive uses of hormonal contraceptives

Obstetrics and Gynecology

Volumn 115, Issue 1, 2010, Pages 206-218

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; DROSPIRENONE; ETHINYLESTRADIOL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; CONTRACEPTIVE AGENT;

ACNE; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DYSMENORRHEA; ENDOMETRIOSIS; ENDOMETRIUM CANCER; FERTILITY; HIRSUTISM; HORMONAL CONTRACEPTION; HUMAN; LEIOMYOMA; MENORRHAGIA; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MENSTRUAL MIGRAINE; NOTE; ORAL CONTRACEPTION; OVARY CANCER; PELVIS PAIN SYNDROME; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; ACNE VULGARIS; ARTICLE; CHEMISTRY; FEMALE; GYNECOLOGIC DISEASE; MENSTRUATION; OVARY CYST; PRACTICE GUIDELINE; UTERUS CANCER;

ACNE VULGARIS; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, HORMONAL; DYSMENORRHEA; ENDOMETRIOSIS; FEMALE; GENITAL DISEASES, FEMALE; HIRSUTISM; HUMANS; LEIOMYOMA; LEVONORGESTREL; MENSTRUATION; OVARIAN CYSTS; PREMENSTRUAL SYNDROME; UTERINE NEOPLASMS;

EID: 74049158321     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181cb50b5     Document Type: Note

References (160)

1. Piccinino LJ, Mosher WD. Trends in contraceptive use in the United States: 1982-1995. Fam Plann Perspect 1998; 30:4-10, 46. (Level II-3)
2. Kaunitz AM. Oral contraceptive health benefits: perception versus reality. Contraception 1999;59:29S-33S. (Level III)
3. David PS, Boatwright EA, Tozer BS, Verma DP, Blair JE, Mayer AP, et al. Hormonal contraception update. Mayo Clin Proc 2006;81:949-54; quiz 955. (Level III)
4. Grimes DA, Lopez LM, Schulz KF, Van Vliet HA, Helmerhorst FM. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD003553. DOI: 10.1002/14651858. CD003553.pub2. (Meta-analysis)
5. Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997;89:615-622 (Level I)
6. Cedars MI. Triphasic oral contraceptives: review and comparison of various regimens. Fertil Steril 2002;77: 1-14. (Level III)
7. Lanes SF, Birmann B, Walker AM, Singer S. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 1992;166:956-961 (Level II-2)
8. Young RL, Snabes MC, Frank ML, Reilly M. A randomized, double-blind, placebo-controlled comparison of the impact of low-dose and triphasic oral contraceptives on follicular development. Am J Obstet Gynecol 1992;167:678-682 (Level I)
9. Grimes DA, Godwin AJ, Rubin A, Smith JA, Lacarra M. Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. Obstet Gynecol 1994;83:29-34. (Level I)
10. Stewart FH, Kaunitz AM, Laguardia KD, Karvois DL, Fisher AC, Friedman AJ. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet Gynecol 2005;105:1389-1396 (Level I)
11. LaGuardia KD, Fisher AC, Bainbridge JD, LoCoco JM, Friedman AJ. Suppression of estrogen-withdrawal headache with extended transdermal contraception. Fertil Steril 2005;83:1875-1877 (Level 1)
12. White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. Am J Obstet Gynecol 2005;192:2055-2059 (Level I)
13. Milsom I, Lete I, Bjertnaes A, Rokstad K, Lindh I, Gruber CJ, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. Hum Reprod 2006;21:2304-2311 (Level I) (Pubitemid 44530604)
14. Roumen FJ. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. Contraception 2007; 75:420-429 (Level III)
15. Meirik O, Fraser IS, d'Arcangues C. Implantable contraceptives for women. WHO Consultation on Implantable Contraceptives for Women. Hum Reprod Update 2003; 9:49-59. (Level III)
16. Bragheto AM, Caserta N, Bahamondes L, Petta CA. Effectiveness of the levonorgestrel-releasing intrauter-ine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception 2007;76:195-199 (Level III)
17. Cho S, Nam A, Kim H, Chay D, Park K, Cho DJ, et al. Clinical effects of the levonorgestrel-releasing intrauter-ine device in patients with adenomyosis. Am J Obstet Gynecol 2008;198:373.e1-373.e7. (Level III)
18. Kaunitz AM. Progestin-releasing intrauterine systems and leiomyoma. Contraception 2007;75:S130-3. (Level III)
19. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol Obstet Invest 2005;59:29-35. (Level II-3)
20. Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod 2005;20:789-793 (Level II-3)
21. Petta CA, Ferriani RA, Abrão MS, Hassan D, Rosa E Silva JC, et al. A 3-year follow-up of women with endo-metriosis and pelvic pain users of the levonorgestrel-releasing intrauterine system. Eur J Obstet Gynecol Reprod Biol 2009;143:128-129 (Level I)
22. Abou-Setta AM, Al-Inany HG, Farquhar C. Levo-norgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. Cochrane Menstrual Disorders and Subfertility Group Cochrane Database of Systematic Reviews 3, 2009. (Meta-analysis)
23. Lukes AS, Reardon B, Arepally G. Use of the levonor-gestrel-releasing intrauterine system in women with hemo-static disorders. Fertil Steril 2008;90:673-677 (Level III)
24. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002;57:120-128 (Level III)
25. Jamieson DJ, Steege JF. The prevalence of dysmenor-rhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. Obstet Gynecol 1996; 87:55-58 (Level II-3)
26. Hendrix SL, Alexander NJ. Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception 2002;66:393-399 (Level 1)
27. Winkler UH, Ferguson H, Mulders JA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception 2004;69:469-476 (Level 1)
28. Milsom I, Sundell G, Andersch B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception 1990;42:497-506. (Level II-2)
29. Hohmann H, Creinin MD. The contraceptive implant. Clin Obstet Gynecol 2007;50:907-917 (Level III)
30. Funk S, Miller MM, Mishell DR Jr, Archer DF, Poindexter A, Schmidt J, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Implanon US Study Group. Contraception 2005;71:319-326 (Level III)
31. Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000;5(suppl 2):21-28 (Level III)
32. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol 2006;125:9-28. (Level III)
33. Harada T, Momoeda M, Taketani Y, Hoshiai H, Terakawa N. Low-dose oral contraceptive pill for dys-menorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2008;90:1583-1588 (Level I)
34. Surrey ES. The role of progestins in treating the pain of endometriosis. J Min Invasive Gynecol 2006;13:528-534 (Level III)
35. Walch K, Unfried G, Huber J, Kurz C, van Trotsenburg M, Pernicka E, et al. Implanon versus medroxyproges-terone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study. Contraception 2009;79:29-34 (Level I)
36. Fedele L, Bianchi S, Zanconato G, Portuese A, Raffaelli R. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis Fertility and Sterility 2001;75:485-488. (Level II-2)
37. Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. Comparison of a levonorgestrel-releas-ing intrauterine device versus expectant management after conservative surgery for symptomatic endometrio-sis: a pilot study. Fertil Steril 2003:80;305-309 (Level I)
38. Steinauer J, Autry AM. Extended cycle combined hormonal contraception. Obstet Gynecol Clin North Am 2007;34:43-55, viii. (Level III)
39. Landgren BM, Diczfalusy E. Hormonal effects of the 300 microgram norethisterone (NET) minipill. I. Daily steroid levels in 43 subjects during a pretreatment cycle and during the second month of NET administration. Contraception 1980;21:87-113. (Level III)
40. Kim-Bjorklund T, Landgren BM, Hamberger L. Is the contraceptive effect of 300 micrograms of norethisterone mainly peripheral or central? Contraception 1992;45:57-66. (Level II-2)
41. Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006;74:439-445 (Level II-3)
42. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492-501. (Level I)
43. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261-266 (Level II-3)
44. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002;186:1142-1149 (Level II-3)
45. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive [published erratum appears in Contraception 2004;69:175]. Contraception 2003;68:89-96. (Level I)
46. Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007;75:444-449 (Level I)
47. Sulak PJ, Smith V, Coffee A, Witt I, Kuehl AL, Kuehl TJ. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. Obstet Gynecol 2008; 112:563-571 (Level I)
48. Prentice A. Health care implications of dysfunctional uterine bleeding. Baillieres Best Pract Res Clin Obstet Gynaecol 1999;13:181-188 (Level III)
49. McKenna DM, Dockeray CJ, McCann SR. Iron deficiency in pre-menopausal females. Ir Med J 1989;82:69-70. (Level III)
50. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss-a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45:320-351 (Level III)
51. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol 1991;31:66-70. (Level I)
52. Larsson G, Milsom I, Lindstedt G, Rybo G. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception 1992;46: 327-334 (Level III)
53. Milman N, Clausen J, Byg KE. Iron status in 268 Danish women aged 18-30 years: influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol 1998;77:13-19 (Level II-2)
54. Braunstein JB, Hausfeld J, Hausfeld J, London A. Economics of reducing menstruation with trimonthly-cycle oral contraceptive therapy: comparison with standard-cycle regimens. Obstet Gynecol 2003;102:699-708. (Level III)
55. Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 2001;98:771-778 (Level I)
56. Sulak PJ, Carl J, Gopalakrishnan I, Coffee A, Kuehl TJ. Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding. Contraception 2004;70:281-287 (Level II-3)
57. Power J, French R, Cowan F. Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods for preventing pregnancy. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD001326. DOI: 10. 1002/14651858.CD001326.pub2. (Meta-analysis)
58. Istre O, Trolle B. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Fertil Steril 2001;76:304-309 (Level I)
59. Barrington JW, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol 1997;104:614-616 (Level III)
60. Tang GW, Lo SS. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. Contraception 1995;51:231-235 (Level III)
61. Andersson JK, Rybo G. Levonorgestrel-releasing intra-uterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990;97:690-694 (Level III)
62. Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999;78:716-721 (Level III)
63. Crosignani PG, Vercellini P, Mosconi P, Oldani S, Cortesi I, De Giorgi O. Levonorgestrel-releasing intra-uterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997;90:257-263 (Level I)
64. Varila E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001;76:969-973 (Level III)
65. Hurskainen R, Paavonen J. Levonorgestrel-releasing intrauterine system in the treatment of heavy menstrual bleeding. Curr Opin Obstet Gynecol 2004;16:487-490 (Level III)
66. Lethaby A, Cooke I, Rees MC. Progesterone or pro-gestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD002126. DOI: 10.1002/14651858. CD002126.pub2. (Meta-analysis)
67. Kaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 2009;113:1104-1116 (Meta-analysis)
68. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD003855. DOI: 10.1002/14651858.CD003855.pub2. (Meta-analysis)
69. Blumenthal PD, Trussell J, Singh RH, Guo A, Borenstein J, Dubois RW, et al. Cost-effectiveness of treatments for dysfunctional uterine bleeding in women who need contraception. Contraception 2006;74:249-258 (Level III)
70. Bancroft J, Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms. J Psychosom Res 1993; 37:195-202. (Level II-3)
71. Joffe H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 2003;189:1523-1530 (Level II-3)
72. Andersch B. The effect of various oral contraceptive combinations on premenstrual symptoms. Int J Gynaecol Obstet 1982;20:463-469 (Level II)
73. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992;36:257-266 (Level II-2)
74. Reid RL, Case AM. Premenstrual syndrome and menstrual-related disorders. In: Falcone T, Hurd WW, editors. Clinical reproductive medicine and surgery. Philadelphia (PA): Mosby Elsevier; 2007. p. 335-351 (Level III)
75. Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. PMS/PMDD Research Group. J Womens Health Gend Based Med 2001;10:561-569 (Level II-1)
76. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414-421 (Level II-3)
77. Joffe H, Petrillo LF, Viguera AC, Gottshcall H, Soares CN, Hall JE, et al. Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report. J Clin Psychiatry 2007;68:1954-1962 (Level I)
78. Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: Comparison of a 21/7 and extended regimen. AJOG 2006;156:1311-1319 (Level II-2)
79. Case AM, Reid RL. Effects of the menstrual cycle on medical disorders. Arch Intern Med 1998;158:1405-1412 (Level III)
80. Digre K, Damasio H. Menstrual migraine: differential diagnosis, evaluation, and treatment. Clin Obstet Gynecol 1987;30:417-430 (Level III)
81. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 1993;33:385-389 (Level III)
82. Nelson AL. Extended-cycle oral contraception: a new option for routine use. Treat Endocrinol 2005;4:139-145 (Level III)
83. Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril 2006; 85:436-440 (Level I)
84. Breitkopf DM, Rosen MP, Young SL, Nagamani M. Efficacy of second versus third generation oral contracp-ties in the treatment of hirsutism. Contraception 2003; 26:349-353 (Level I)
85. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD004425. DOI: 10.1002/ 14651858.CD004425.pub4. (Meta-analysis)
86. Kaufman DW, Shapiro S, Slone D, Rosenberg L, Miettinen OS, Stolley PD, et al. Decreased risk of endome-trial cancer among oral-contraceptive users. N Engl J Med 1980;303:1045-1047 (Level II-2)
87. Kelsey JL, LiVolsi VA, Holford TR, Fischer DB, Mostow ED, Schwartz PE, et al. A case-control study of cancer of the endometrium. Am J Epidemiol 1982; 116:333-342 (Level II-2)
88. Hulka BS, Chambless LE, Kaufman DG, Fowler WC Jr, Greenberg BG. Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA 1982;247:475-477 (Level II-2)
89. Jick SS, Walker AM, Jick H. Oral contraceptives and endometrial cancer. Obstet Gynecol 1993;82:931-935 (Level II-2)
90. Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999;10:277-284 (Level II-2) (Pubitemid 29358961)
91. La Vecchia C, Altieri A, Franceschi S, Tavani A. Oral contraceptives and cancer: An update. Drug Safety 2001; 24:741-754 (Level III)
92. Centers for Disease Control. Oral contraceptive use and the risk of endometrial cancer. JAMA 1983;249:1600-1604 (Level II-2)
93. Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A. The epidemiology of endometrial cancer in young women. Br J Cancer 1983;47:749-756 (Level II-2)
94. Stanford JL, Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, et al. Oral contraceptives and endometrial cancer: do other risk factors modify the association? Int J Cancer 1993;54:243-248 (Level II-2)
95. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. Hum Reprod 1997;12:1851-1863 (Level III)
96. Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003;362:185-191 (Level II-2) (Pubitemid 36859933)
97. Voigt LF, Deng Q, Weiss NS. Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA). Cancer Causes Control 1994;5:227-233 (Level III)
98. Rosenblatt KA, Thomas DB. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991;49:870-874 (Level II-2)
99. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991;49:186-190 (Level II-2)
100. Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med 1996;41:419-427 (Level III)
101. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using levonorgestrel-releasing IUD. Clin Endocrinol 1982;17: 529-536 (Level II-3)
102. Sturdee D. Levonorgestrel intrauterine system for endo-metrial protection. J Br Menopause Soc 2006;(suppl 1): 1-3. (Level III)
103. Haimovich S, Checa MA, Mancebo G, Fuste P, Carreras R. Treatment of endometrial hyperplasia without atypia in peri-and postmenopausal women with a levonor-gestrel intrauterine device. Menopause 2008;15:1002-1004 (Level III)
104. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008;139:169-175 (Level II)
105. Wildemeersch D, Janssens D, Pylyser K, De Wever N, Verbeeck G, Dhont M, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 2007;57:210-213 (Level III)
106. Buttini MJ, Jordan SJ, Webb PM. The effect of the levo-norgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. Aust N Z J Obstet Gynaecol 2009;49:316-322 (systematic review)
107. Kresowik J, Ryan GL, Van Voorhis BJ. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levo-norgestrel-releasing intrauterine system. Obstet Gynecol 2008;111:547-549 (Level III)
108. Clark TJ, Neelakantan D, Gupta JK. The management of endometrial hyperplasia: An evaluation of current practice. EJOG 2006;125:259-264 (Level III)
109. Chan SS, Tam WH, Yeo W, Yu MM, Ng DP, Wong AW, et al. A randomised controlled trial of prophylactic levo-norgestrel intrauterine system in tamoxifen-treated women. BJOG 2007;114:1510-1515 (Level I)
110. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemio-logical studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371:303-314 (Meta-analysis)
111. Ness RB, Grisso JA, Klapper J, Schlesselman JJ, Silberzweig S, Vergona R, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol 2000;152:233-241 (Level II-2)
112. Grenader T, Peretz T, Lifchitz M, Shavit L. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use. Breast 2005;14:264-268 (Level III)
113. Fernandez E, La Vecchia C, Balducci A, Chatenoud L, Franceschi S, Negri E. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer 2001;84:722-727 (Meta-analysis) (Pubitemid 32239011)
114. Hannaford P, Elliott A. Use of exogenous hormones by women and colorectal cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. Contraception 2005;71:95-98 (Level II-2)
115. Christensen JT, Boldsen JL, Westergaard JG. Functional ovarian cysts in premenopausal and gynecologically healthy women. Contraception 2002;66:153-157 (Level III)
116. Holt VL, Daling JR, McKnight B, Moore D, Stergachis A, Weiss NS. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstet Gynecol 1992;79:529-533 (Level II-2)
117. Steinkampf MP, Hammond KR, Blackwell RE. Hormonal treatment of functional ovarian cysts: a randomized, prospective study. Fertil Steril 1990;54:775-777 (Level I)
118. Turan C, Zorlu CG, Ugur M, Ozcan T, Kaleli B, Gokmen O. Expectant management of functional ovarian cysts: an alternative to hormonal therapy. Int J Gynaecol Obstet 1994;47:257-260 (Level II-1)
119. MacKenna A, Fabres C, Alam V, Morales V. Clinical management of functional ovarian cysts: a prospective and randomized study. Hum Reprod 2000;15:2567-2569 (Level I)
120. Bayar U, Barut A, Ayoglu F. Diagnosis and management of simple ovarian cysts. Int J Gynaecol Obstet 2005;91:187-188 (Level II-1)
121. Tayob Y, Adams J, Jacobs HS, Guillebaud J. Ultrasound demonstration of increased frequency of functional ovarian cysts in women using progestogen-only oral contraception. Br J Obstet Gynaecol 1985;92:1003-1009 (Level-II-3)
122. Hidalgo MM, Lisondo C, Juliato CT, Espejo-Arce X, Monteiro I, Bahamondes L. Ovarian cysts in users of Implanon and Jadelle subdermal contraceptive implants. Contraception 2006;73:532-536 (Level II-3)
123. Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol 2005;105:1114-1118 (Level III)
124. Kleerekoper M, Brienza RS, Schultz LR, Johnson CC. Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research Group. Arch Intern Med 1991;151:1971-1976 (Level II-3)
125. Lindsay R, Tohme J, Kanders B. The effect of oral contraceptive use on vertebral bone mass in pre-and post-menopausal women. Contraception 1986;34:333-340 (Level II-2)
126. Lloyd T, Buchanan JR, Ursino GR, Myers C, Woodward G, Halbert DR. Long-term oral contraceptive use does not affect trabecular bone density. Am J Obstet Gynecol 1989;160:402-404 (Level II-2)
127. Lloyd T, Taylor DS, Lin HM, Matthews AE, Eggli DF, Legro RS. Oral contraceptive use by teenage women does not affect peak bone mass: a longitudinal study. Fertil Steril 2000;74:734-738 (Level II-2)
128. Garnero P, Sornay-Rendu E, Delmas PD. Decreased bone turnover in oral contraceptive users. Bone 1995;16:499-503. (Level II-2)
129. Enzelsberger H, Metka M, Heytmanek G, Schurz B, Kurz C, Kusztrich M. Influence of oral contraceptive use on bone density in climacteric women. Maturitas 1988;9:375-378 (Level III)
130. Recker RR, Davies KM, Hinders SM, Heaney RP, Stegman MR, Kimmel DB. Bone gain in young adult women. JAMA 1992;268:2403-2408 (Level II-2)
131. Gambacciani M, Ciaponi M, Cappagli B, Benussi C, Genazzani AR. Longitudinal evaluation of perimeno-pausal femoral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Osteoporos Int 2000;11:544-548 (Level I)
132. Hartard M, Bottermann P, Bartenstein P, Jeschke D, Schwaiger M. Effects on bone mineral density of low-dosed oral contraceptives compared to and combined with physical activity. Contraception 1997;55:87-90. (Level II-3)
133. Kuohung W, Borgatta L, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception 2000;61:77-82. (Level III)
134. Martins SL, Curtis KM, Glasier AF. Combined hormonal contraception and bone health: a systematic review. Contraception 2006;73:445-469 (Meta-analysis)
135. Teegarden D, Legowski P, Gunther CW, McCabe GP, Peacock M, Lyle RM. Dietary calcium intake protects women consuming oral contraceptives from spine and hip bone loss. J Clin Endocrinol Metab 2005;90:5127-5133 (Level I)
136. Lopez LM, Grimes DA, Schulz KF, Curtis KM. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD006033. DOI: 10.1002/14651858.CD006033. pub3. (Meta-analysis)
137. La Vecchia C, Tavani A, Gallus S. Oral contraceptives and risk of hip fractures. Lancet 1999;354:335-336 (Level III)
138. Mallmin H, Ljunghall S, Persson I, Bergstrom R. Risk factors for fractures of the distal forearm: a population-based case-control study. Osteoporos Int 1994;4:298-304. (Level II-2)
139. Tuppurainen M, Kroger H, Saarikoski S, Honkanen R, Alhava E. The effect of previous oral contraceptive use on bone mineral density of perimenopausal women. Osteoporosis International 1994;4:93-98 (Level II-3)
140. Cooper C, Hannaford P, Croft P, Kay CR. Oral contraceptive pill use and fractures in women: a prospective study. Bone 1993;14:41-45 (Level II-2)
141. Barad D, Kooperberg C, Wactawski-Wende J, Liu J, Hendrix SL, Watts NB. Prior oral contraception and postmenopausal fracture: a Women's Health Initiative observational cohort study. Fertil Steril 2005;84:374-383 (Level II-2) (Pubitemid 41125258)
142. Vessey M, Mant J, Painter R. Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort study. Contraception 1998; 57:231-235 (Level II-2)
143. Johansson C, Mellstrom D. An earlier fracture as a risk factor for new fracture and its association with smoking and menopausal age in women. Maturitas 1996;24:97-106. (Level II-2)
144. O'Neill TW, Marsden D, Adams JE, Silman AJ. Risk factors, falls, and fracture of the distal forearm in Manchester, UK. J Epidemiol Community Health 1996; 50:288-292 (Level II-2)
145. O'Neill TW, Silman AJ, Naves Diaz M, Cooper C, Kanis J, Felsenberg D. Influence of hormonal and reproductive factors on the risk of vertebral deformity in European women. European Vertebral Osteoporosis Study Group. Osteoporos Int 1997;7:72-78 (Level II-3)
146. Massai R, Makarainen L, Kuukankorpi A, Klipping C, Duijkers I, Dieben T. The combined contraceptive vaginal ring and bone mineral density in healthy pre-menopausal women. Hum Reprod 2005;20:2764-2768 (Level II-1)
147. Cundy T, Cornish J, Roberts H, Elder H, Reid IR. Spinal bone density in women using depot medroxyproges-terone contraception. Obstet Gynecol 1998;92:569-573 (Level II-3)
148. Di X, Li Y, Zhang C, Jiang J, Gu S. Effects of levo-norgestrel-releasing subdermal contraceptive implants on bone density and bone metabolism. Contraception 1999; 60:161-166 (Level I)
149. Bahamondes L, Monteiro-Dantas C, Espejo-Arce X, Dos Santos Fernandes AM, Lui-Filho JF, Perrotti M, et al. A prospective study of the forearm bone density of users of etonorgestrel-and levonorgestrel-releasing contraceptive implants. Hum Reprod 2006;21:466-470 (Level I)
150. Berenson AB, Rahman M, Breitkopf CR, Bi LX. Effects of depot medroxyprogesterone acetate and 20-micro-gram oral contraceptives on bone mineral density. Obstet Gynecol 2008;112:788-799 (Level II-3)
151. Gourlay ML, Brown SA. Clinical considerations in pre-menopausal osteoporosis. Arch Intern Med 2004;164: 603-614 (Level III)
152. Kaunitz AM. Depo-Provera's black box: time to reconsider? Contraception 2005;72:165-167 (Level III)
153. Rosenberg L, Zhang Y, Constant D, Cooper D, Kalla AA, Micklesfield L, et al. Bone status after cessation of use of injectable progestin contraceptives. Contraception 2007;76:425-431 (Level II-2)
154. Parazzini F, Negri E, La Vecchia C, Fedele L, Rabaiotti M, Luchini L. Oral contraceptive use and risk of uterine fibroids. Obstet Gynecol 1992;79:430-433 (Level II-2)
155. Chiaffarino F, Parazzini F, La Vecchia C, Marsico S, Surace M, Ricci E. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol 1999;106:857-860 (Level II-2)
156. Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives [published erratum appears in Br Med J 1986;293:1027]. Br Med J 1986;293:359-362 (Level II-2)
157. Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004;159:113-123 (Level II-2)
158. Marshall LM, Spiegelman D, Goldman MB, Manson JE, Colditz GA, Barbieri RL, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998;70:432-439 (Level II-2)
159. Carr BR, Marshburn PB, Weatherall PT, Bradshaw KD, Breslau NA, Byrd W, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxy-progesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993;76:1217-1223 (Level II-3)
160. Magalhaes J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrha-gia or menorrhagia due to leiomyomas. Contraception 2007;75:193-198 (Level II-2)